Amgen Becomes A Biotech Safety Stock (AMGN)

Health and Healthcare

Published: October 22, 2008 3:15 pm

Last Updated: April 27, 2020 3:52 pm

Amgen_logo Amgen Inc. (NASDAQ: AMGN) has just posted earnings. The biotech giant for anemia treatments posted $1.09 GAAP EPS and adjusted earnings of $1.23 non-GAAP EPS and $3.875 billion in revenues. First Call had estimates pegged at $1.08 EPS on revenues of $3.7 billion.

The company has also now raised full-year guidance to $4.45 to $4.55EPS from the prior range of $4.25 to $4.45 EPS. First call hasestimates at $4.38 EPS.

Aranesp sales were up at $845 million and it saw $634 million in Epogen sales, both of which were above estimates.

Shares closed down over 4.7% at $49.92 for an unofficial closing price,but shares are flying high up around the $53.00 mark in after-hourstrading. The 52-week trading range is $39.16 to $66.51.

Jon C. Ogg
October 22, 2008

Are You Ahead, or Behind on Retirement? (sponsor)

If you’re one of the over 4 Million Americans set to retire this year, you may want to pay attention.

Finding a financial advisor who puts your interest first can be the difference between a rich retirement and barely getting by, and today it’s easier than ever. SmartAsset’s free tool matches you with up to three fiduciary financial advisors that serve your area in minutes. Each advisor has been carefully vetted, and must act in your best interests. Start your search now.

Don’t waste another minute; get started right here and help your retirement dreams become a retirement reality.